Skip to main content

Market Overview

Bristol-Myers Squibb Analyst Sees Multiple Expansion Story, Limited Near-Term Downside Risk

Bristol-Myers Squibb Analyst Sees Multiple Expansion Story, Limited Near-Term Downside Risk

An analyst at Guggenheim Securities turned bullish on pharma giant Bristol-Myers Squibb Co (NYSE: BMY) Monday, basing their optimism on a revival in sales of its flagship immuno-oncology drug Opdivo.

The Bristol-Myers Squibb Analyst:  Analyst Seamus Fernandez upgraded Bristol-Myers Squibb shares from Neutral to Buy with a new $70 price target. 

The Bristol-Myers Squibb Thesis: Opdivo is stabilizing, with positive best-in-class data across several first-line and early stage cancers, Fernandez said in the upgrade note. 

Peak Opdivo sales will likely be more than $11 billion in 2025 through the U.S. patent expiration in 2028, the analyst said. 

This estimate is based on a revised model that includes early stage cancers and the incremental impact of first-line metastatic successes, along with physician checks suggesting solid early uptake of Opdivo + Yervoy in PDL1 low and negative lung cancer, he said. 

The consensus Opdivo sales are achievable, with upside optionality in 2022 and beyond, Fernandez said. 

Related Link: The Week Ahead In Biotech: Spectrum Pharma FDA Decision, Biogen And Abbott Earnings, Cancer Conference

"BMY is a multiple expansion story with limited near-term downside risk, in our view," the analyst said. 

Guggenheim sees several drivers of multiple expansion, including Opdivo's return to growth as a key driver of the base business, execution on new product launches and incremental 2021/22 potential pipeline catalysts not factored into the sell-side firm's model, he said. 

New product launches include Zeposia in multiple sclerosis and ulcerative colitis, Reblozyl in myelodysplastic syndromes and anemia and Onureg, Fernandez said.

Among the unaccounted pipeline catalysts are Factor Xia and Opdivo + Yervoy combination in stage 3 unresectable non-small cell lung cancer, the analyst said. 

Guggenheim is particularly favorable on the near-term risk-reward for the stock.

BMY Price Action: At last check, Bristol-Myers Squibb shares were down 1.11% at $60.57. 

Related Link: 9 Biotech Stocks With Material Catalysts In Q4

Latest Ratings for BMY

Apr 2021Truist SecuritiesUpgradesHoldBuy
Nov 2020Societe GeneraleUpgradesHoldBuy
Nov 2020BernsteinReinstatesMarket Perform

View More Analyst Ratings for BMY
View the Latest Analyst Ratings


Related Articles (BMY)

View Comments and Join the Discussion!

Posted-In: Guggenheim Securities Seamus FernandezAnalyst Color Biotech Upgrades Price Target Analyst Ratings Best of Benzinga

Latest Ratings

VZIOWells FargoInitiates Coverage On31.0
OMWells FargoInitiates Coverage On63.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at